Market Cap | 1.22B | P/E | - | EPS this Y | 1.70% | Ern Qtrly Grth | - |
Income | -220.31M | Forward P/E | -6.79 | EPS next Y | 31.90% | 50D Avg Chg | 8.00% |
Sales | 295.21M | PEG | -0.08 | EPS past 5Y | - | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 1.74 | EPS next 5Y | 150.00% | 52W High Chg | -64.00% |
Recommedations | 2.10 | Quick Ratio | 4.37 | Shares Outstanding | 58.59M | 52W Low Chg | 87.00% |
Insider Own | 1.72% | ROA | -16.39% | Shares Float | 57.70M | Beta | 1.76 |
Inst Own | 109.18% | ROE | -38.36% | Shares Shorted/Prior | 8.94M/9.21M | Price | 21.39 |
Gross Margin | 40.53% | Profit Margin | -74.63% | Avg. Volume | 1,268,609 | Target Price | 53.49 |
Oper. Margin | -54.00% | Earnings Date | Nov 15 | Volume | 1,361,700 | Change | -6.55% |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Green Paula | SVP of Human Resourc.. SVP of Human Resources | Sep 16 | Option | 5.95 | 8,514 | 50,658 | 22,610 | 09/20/22 |
Green Paula | SVP of Human Resourc.. SVP of Human Resources | Sep 16 | Sell | 37.43 | 8,514 | 318,679 | 14,199 | 09/20/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Aug 16 | Option | 11.59 | 9,000 | 104,310 | 47,831 | 08/18/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Aug 16 | Sell | 50.06 | 13,900 | 695,834 | 38,831 | 08/18/22 |
Banyai William | See Remarks See Remarks | Jul 22 | Sell | 43.19 | 378 | 16,326 | 258,729 | 07/26/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Apr 14 | Option | 20.53 | 6,620 | 135,909 | 53,308 | 04/18/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Apr 14 | Sell | 43.12 | 6,620 | 285,454 | 46,688 | 04/18/22 |
Banyai William | See Remarks See Remarks | Apr 01 | Sell | 53.61 | 318 | 17,048 | 262,455 | 04/05/22 |
Banyai William | See Remarks See Remarks | Feb 18 | Sell | 52.66 | 1,280 | 67,405 | 263,073 | 02/23/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Feb 18 | Option | 25 | 3,517 | 87,925 | 51,442 | 02/23/22 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Feb 18 | Sell | 52.86 | 4,442 | 234,804 | 47,000 | 02/23/22 |
Banyai William | See Remarks See Remarks | Jan 24 | Sell | 54.73 | 348 | 19,046 | 265,174 | 01/26/22 |
Banyai William | See Remarks See Remarks | Oct 22 | Sell | 117.39 | 19,791 | 2,323,265 | 306,378 | 10/26/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 21 | Option | 5.95 | 1,740 | 10,353 | 174,222 | 10/25/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 21 | Sell | 120.99 | 1,740 | 210,523 | 172,482 | 10/25/21 |
Weiss Patrick | Chief Operating Offi.. Chief Operating Officer | Oct 13 | Option | 20.17 | 4,906 | 98,954 | 53,902 | 10/15/21 |
Weiss Patrick | Chief Operating Offi.. Chief Operating Officer | Oct 13 | Sell | 104 | 4,906 | 510,224 | 48,996 | 10/15/21 |
Banyai William | See Remarks See Remarks | Oct 13 | Option | 7.39 | 28,181 | 208,258 | 326,457 | 10/15/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 13 | Option | 5.95 | 1,740 | 10,353 | 174,222 | 10/15/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 13 | Sell | 110.16 | 1,740 | 191,678 | 172,482 | 10/15/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 06 | Option | 5.95 | 8,700 | 51,765 | 174,222 | 10/08/21 |
Leproust Emily M. | President & CEO President & CEO | Oct 06 | Sell | 99.05 | 8,700 | 861,735 | 172,482 | 10/08/21 |
Leproust Emily M. | President & CEO President & CEO | Sep 13 | Sell | 118.46 | 29,587 | 3,504,876 | 219,143 | 09/13/21 |
Leproust Emily M. | President & CEO President & CEO | Sep 13 | Option | 7.39 | 29,587 | 218,648 | 233,063 | 09/13/21 |
JOHANNESSEN JAN | Director Director | Aug 20 | Option | 14 | 5,000 | 70,000 | 6,898 | 08/20/21 |
JOHANNESSEN JAN | Director Director | Aug 20 | Sell | 97.11 | 5,000 | 485,550 | 1,898 | 08/20/21 |
Weiss Patrick | Chief Operating Offi.. Chief Operating Officer | May 21 | Option | 20.17 | 4,905 | 98,934 | 57,109 | 05/21/21 |
JOHANNESSEN JAN | Director Director | May 21 | Option | 14 | 5,000 | 70,000 | 6,898 | 05/21/21 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Apr 26 | Option | 11.59 | 5,000 | 57,950 | 53,034 | 04/26/21 |
THORBURN JAMES M | Chief Financial Offi.. Chief Financial Officer | Apr 26 | Sell | 133.47 | 5,000 | 667,350 | 48,034 | 04/26/21 |
Leproust Emily M. | President & CEO President & CEO | Apr 15 | Sell | 128.84 | 2,000 | 257,680 | 265,843 | 04/15/21 |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Apr 07 | Option | 19.6 | 2,702 | 52,959 | 45,446 | 04/07/21 |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Apr 07 | Sell | 126.72 | 2,702 | 342,397 | 42,744 | 04/07/21 |
Daniels Mark | See Remarks See Remarks | Feb 26 | Option | 23.33 | 620 | 14,465 | 67,546 | 02/26/21 |
Daniels Mark | See Remarks See Remarks | Feb 26 | Sell | 134.31 | 620 | 83,272 | 66,926 | 02/26/21 |
Banyai William | See Remarks See Remarks | Feb 24 | Sell | 144.18 | 20,275 | 2,923,250 | 440,987 | 02/24/21 |
Leproust Emily M. | President & CEO President & CEO | Feb 11 | Sell | 178.43 | 75,000 | 13,382,250 | 02/11/21 | |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Feb 04 | Option | 19.6 | 2,702 | 52,959 | 46,729 | 02/04/21 |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Feb 04 | Sell | 183.59 | 2,702 | 496,060 | 44,027 | 02/04/21 |
Daniels Mark | See Remarks See Remarks | Feb 01 | Option | 8.82 | 377 | 3,325 | 68,577 | 02/01/21 |
Daniels Mark | See Remarks See Remarks | Feb 01 | Sell | 161.02 | 377 | 60,705 | 68,200 | 02/01/21 |
Green Paula | SVP of Human Resourc.. SVP of Human Resources | Jan 26 | Sell | 193 | 246 | 47,478 | 22,250 | 01/26/21 |
Daniels Mark | See Remarks See Remarks | Jan 26 | Option | 23.33 | 620 | 14,465 | 68,820 | 01/26/21 |
Daniels Mark | See Remarks See Remarks | Jan 26 | Sell | 193 | 905 | 174,665 | 68,200 | 01/26/21 |
Banyai William | See Remarks See Remarks | Jan 26 | Sell | 192.95 | 14,099 | 2,720,402 | 461,937 | 01/26/21 |
Leproust Emily M. | President & CEO President & CEO | Jan 19 | Sell | 182.92 | 10,000 | 1,829,200 | 421,196 | 01/19/21 |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Jan 07 | Option | 19.6 | 2,702 | 52,959 | 46,930 | 01/07/21 |
Finn Patrick John | Chief Commercial Off.. Chief Commercial Officer | Jan 07 | Sell | 132.93 | 2,702 | 359,177 | 44,228 | 01/07/21 |
Daniels Mark | See Remarks See Remarks | Dec 29 | Option | 16.08 | 997 | 16,032 | 69,164 | 12/29/20 |
Daniels Mark | See Remarks See Remarks | Dec 29 | Sell | 167.45 | 997 | 166,948 | 68,787 | 12/29/20 |